Business
Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting
Adult and pediatric patients with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont) achieved clinically meaningful weight
About this update from Neurocrine Biosciences, Inc.
[{"type":"text","content":"Adult and pediatric patients with classic congenital adrenal hyperplasia treated with CRENESSITY® (crinecerfont) achieved clinically meaningful weight reductionsSubstantial improvements in insulin resistance were also observed in both adult and pediatric patients treated with CRENESSITY compared with placebo through one year of treatmentSAN DIEGO, July 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new data from the Phase 3 CAHtalyst™ Adult and Pediatric studies showing favorable trends in improvement of weight-related outcomes in patients with classic congenital adrenal hyperplasia who were treated with CRENESSITY® (crinecerfont) for up to one year. These data were presented at the Endocrine Society's Annual Meeting, ENDO 2025, that is taking place July 12-15 in San Francisco. \n\n \n \n \n \n \n \n\n \n\"It's well established that use of high-dose glucocorticoids pose short- and long-term health risks for people living with congenital adrenal hyperplasia,\" said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. \"These data presented at ENDO, which include both pediatric and adult patients, showed that the reduction in steroid doses enabled by CRENESSITY can lead to meaningful improvements in cardiometabolic outcomes. The use of CRENESSITY with glucocorticoid treatment is evolving the standard of care for classic congenital adrenal hyperplasia.\"\nThe Phase 3 CAHtalyst program was the largest-ever interventional clinical trial program in classic congenital adrenal hyperplasia (CAH) and included 103 pediatric (four to 17 years of age) patients and 182 adult (18 to 58 years of age) patients. Both the CAHtalyst Pediatric study and the CAHtalyst Adult study consisted of an initial six-month, double-blind, placebo-controlled (DBPC) period (28 weeks for the pediatric study and 24 weeks for the adult study) followed by a 24-week open-label (OL) period, during which all patients received CRENESSITY. During both the DBPC and OL periods, glucocorticoid (GC) doses were kept stable for the first four weeks and then decreased as tolerated toward more physiologic levels while maintaining or improving androstenedione (A4) relative to Day 1 baseline.\nAdult and pediatric patients receiving CRENESSITY for up to one year saw improvements in key weight-related outcomes:...